androgen receptor antagonist TAS3681
Term · Oncology and biomedicine · MLC-T-ONC-010067
An orally bioavailable inhibitor of the androgen receptor (AR), with potential antineoplastic activity. Upon oral administration, AR inhibitor TAS3681 specifically binds to AR. This prevents AR activation, downregulates AR and prevents AR-mediated signaling. This inhibits cell growth in AR-overexpressing tumor cells. AR is overexpressed in prostate cancers and is involved in proliferation, survival and chemoresistance of tumor cells.
| Identifier | MLC-T-ONC-010067 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | androgen receptor inhibitor TAS3681; AR antagonist TAS3681 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-010067",
"term": "androgen receptor antagonist TAS3681",
"field": "Oncology and biomedicine",
"definition": "An orally bioavailable inhibitor of the androgen receptor (AR), with potential antineoplastic activity. Upon oral administration, AR inhibitor TAS3681 specifically binds to AR. This prevents AR activation, downregulates AR and prevents AR-mediated signaling. This inhibits cell growth in AR-overexpressing tumor cells. AR is overexpressed in prostate cancers and is involved in proliferation, survival and chemoresistance of tumor cells.",
"synonyms": [
"androgen receptor inhibitor TAS3681",
"AR antagonist TAS3681"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/androgen-receptor-antagonist-tas3681/"
}
Record 1,075 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.